LOTTE BIOLOGICS is a CMO/CDMO company operating in the pharmaceutical industry.
LOTTE BIOLOGICS is a premier global CDMO dedicated to providing top-quality biopharmaceuticals. We have pursued swift global expansion following the acquisition of BMS’ Syracuse site, a location with over 62 international regulatory approvals and a 35,000L production capacity. Our capabilities span from cell line development to biologics drug substance manufacturing, with an ADC conjugation facility planned. Future expansion includes three Mega Plants in Korea with a projected capacity exceeding 360,000L by 2030 with the first plant expected to be GMP-ready by 2026.
Company type
CMO/CDMO
Products and services
Contract Services – Analytical & Lab Services
Markets
North America (USA, Canada), East Asia (e.g. China, Japan, Korea), Europe – EU countries
Useful Links
Connect with LOTTE BIOLOGICS on LinkedIn
Address
LOTTE BIOLOGICS, 300 Olymoic-ro, Songpa-gu, Seoul, Korea, Republic of,
